PSMA and RLT: The VISION and TheraP Trials “Presentation” – Michael Morris
At the 2024 UCSF-UCLA PSMA Conference, Michael Morris reviews the VISION and TheraP trials, underscoring their significance in advancing PSMA PET imaging and radioligand therapy for prostate cancer, particularly highlighting lutetium PSMA-617’s efficacy in improving survival and quality of life as shown in the VISION trial. Dr. Morris stresses the importance of further research to refine patient…